TrialClinical pharmacology and therapeutics2025

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Chi-Chung Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.